Kết quả sớm của phương pháp nút mạch hóa chất ở bệnh nhân ung thư biểu mô tế bào gan có huyết khối tĩnh mạch cửa tại Bệnh viện K Tân Triều

This study aimed to evaluate short-term outcomeof Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients with portal vein thrombosis. A quasi-experimental study was conducted in 38 patients with HCC. Treatment responses of TACE were evaluated by mRECIST at 1 to 3 month and 6 month post-intervention. After 1 - 3 months of TACE, the percentage of partial response, stable disease and progressive disease were 34.2%, 63.2%, and 2.6%, respectively. These figures for 6 months post-intervention were 44.4%, 16.7%, and 33.3%, respectively. Notably, 5.6% of patient response completely to the treatment. Tumor and thrombosis size decreased statistically significantly after TACE compared to before treatment (p < 0.01). Post-embolism syndromes are common such as liver pain, fever, fatigue and nausea and/or vomiting but are mostly mild. Low complication rate: 2.6% had new nodules in the liver; 2.6% had secondary to extrahepatic after 1 to 3 months of intervention. There were no deaths related to TACE. In conclusion, TACE is relative safety and have efficacy in treatment of HCC patients with portal vein thrombosis.